Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pa...
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: Yahoo! Finance
Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX Further deepening of tumor shrinkage was evident with additional objective responses over long treatment duration Results demonstrate an unprecedented median Duration of Response of 12.6 months and confirm immunotherapeutic contribution of mitazalimab when added to chemotherapy With a median 18-month follow-up duration, these results from the ongoing OPTIMIZE-1 trial validate and strengthen mitazalimab's previously reported robust clinical benefit Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company's lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of mitazalimab (CD40 mAb agonist) in combination with standard of care chemotherapy mFOLFIRINOX, in
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq RulesAccesswire
- Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025 [Yahoo! Finance]Yahoo! Finance
- Aptevo Participating in the BIO International ConventionAccesswire
- Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology [Yahoo! Finance]Yahoo! Finance
APVO
Sec Filings
- 6/28/24 - Form 424B4
- 6/26/24 - Form S-1/A
- 6/14/24 - Form S-1
- APVO's page on the SEC website